Ⓐ
PeptiBrief
Peptide · Drug class or analogue

Amylin Analogue

Research peptide
Aliases · Pramlintide · Synthetic amylin analogue

A class of amylin-receptor agonists that slow gastric emptying, suppress post-meal glucagon and increase satiety. Evidence and regulatory status vary substantially by molecule.

Human
2/5
Animal
0/5
In-vitro
0/5
Safety
2/5
Last reviewed · 7/11/2026
Compare with another peptide →
Last reviewed7/11/2026
Evidence statusEarly entry
Published references0
Trust signal panel
Evidence & safety
  • Human evidence
    n/a
  • Animal evidence
    n/a
  • Mechanistic
    n/a
  • Safety knowledge
    n/a
  • Editorial confidence
    5/5
View in knowledge graph →See this peptide connected to conditions & mechanisms
01

Evidence Snapshot

Evidence snapshot · 2 verified refs
Overall
2/5Emerging / preliminary
Human
2/5Some human clinical evidence
Animal
0/5None identified
In-vitro
0/5None identified
Safety
2/5Partially characterised safety
02

Scientific identity

Peptide family
Amylin receptor agonist
Entity class
Drug class or analogue
Alternative names
PramlintideSynthetic amylin analogue
Discovery history

Developed to reproduce amylin signalling while reducing the aggregation tendency of native human amylin; pramlintide became the first clinically used analogue.

02

Proposed Mechanisms

03

Reported / Studied Uses

04

Human Evidence

Pramlintide has established clinical evidence as an adjunct to insulin in type 1 and insulin-treated type 2 diabetes. Other analogues may be investigational or represented separately in Atlas.

05

Animal Evidence

Animal studies support reduced food intake, weight effects and altered glucose handling.

Species translation to humans is uncertain.
06

Safety & Unknowns

prescription-medicine-classnausea-riskhypoglycaemia-with-insulingastric-emptying-delay
Nausea is common. Severe hypoglycaemia can occur when used with insulin unless mealtime insulin is appropriately reduced. It can delay absorption of oral medicines and is unsuitable in gastroparesis.
07

Regulatory Status

CountryStatusNotes
08

Community Observations

No approved community reports yet. Submit one. Aggregate data is observational only.
09

References

  • No verified references linked yet. Editors will add primary sources.
10

Full Disclaimer

This page is for educational information only. It does not constitute medical advice, diagnosis, treatment, dosing guidance, or a recommendation to use any peptide, medicine or research chemical. Many peptides discussed on Atlas are not approved for human use in most jurisdictions and may have limited or unknown long-term safety data.

Community observations shown on this page are anonymised, moderated and observational only. They do not establish safety or effectiveness.

Always consult a qualified healthcare professional before making decisions about your health. See medical disclaimer and methodology.

↳

Explore further

from the knowledge graph
Advertise here — support independent evidence →
ImportantPeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.